David Jonathan Heineman1, Martijn Geert Ten Berge2, Johannes Marlene Daniels3, Michaël Ignatius Versteegh4, Perla Jacqueline Marang-van de Mheen5, Michael Wilhelmus Wouters6, Wilhelmina Hendrika Schreurs7. 1. Department of Surgery, Medisch Centrum Alkmaar, Alkmaar, the Netherlands. Electronic address: david.heineman@gmail.com. 2. Department of Surgery, Leiden University Medical Center, Leiden, the Netherlands. 3. Department of Pulmonary Diseases, VU University Medical Centre, Amsterdam, the Netherlands. 4. Department of Cardiothoracic Surgery, Leiden University Medical Center, Leiden, the Netherlands. 5. Department of Medical Decision Making, Leiden University Medical Center, Leiden, the Netherlands. 6. Department of Surgical Oncology, Antoni van Leeuwenhoek Hospital/Netherlands Cancer Institute, Amsterdam, the Netherlands; Scientific Bureau, Dutch Institute for Clinical Auditing, Leiden, the Netherlands. 7. Department of Surgery, Medisch Centrum Alkmaar, Alkmaar, the Netherlands.
Abstract
BACKGROUND: Clinical staging of non-small cell lung cancer (NSCLC) determines the initial treatment offered to a patient. The similarity between clinical and pathologic staging in some studies is as low as 50%, and others publish results as high as 91%. The Dutch Lung Surgery Audit is a clinical database that registers the clinical and pathologic TNM of almost all NSCLC patients who undergo operations in the Netherlands. The objective of this study was to determine the accuracy of clinical staging of NSCLC. METHODS: Prospective data were derived from the Dutch Lung Surgery Audit in 2013 and 2014. Patients were included if they had undergone a surgical resection for stage IA to IIIB NSCLC without neoadjuvant treatment and had a positron emission tomography-computed tomography scan as part of the clinical workup. Clinical (c)TNM and pathologic (p)TNM were compared, and whether discrepancy was based on tumor or nodal staging was determined. RESULTS: From 2,834 patients identified, 2,336 (82.4%) fulfilled the inclusion criteria and had complete data. Of these 2,336, 1,276 (54.6%) were staged accurately, 707 (30.3%) were clinically understaged, and 353 (15.1%) were clinically overstaged. In the understaged group, 346 patients had a higher pN stage (14.8%), of which 148 patients had unforeseen N2 disease (6.3%). In the overstaged group, 133 patients had a cN that was higher than the pN (5.7%). CONCLUSIONS: Accuracy of NSCLC staging in the Netherlands is low (54.6%), even in the era of positron emission tomography-computed tomography. Especially accurate nodal staging remains challenging. Future efforts should include the identification of specific pitfalls in NSCLC staging.
BACKGROUND: Clinical staging of non-small cell lung cancer (NSCLC) determines the initial treatment offered to a patient. The similarity between clinical and pathologic staging in some studies is as low as 50%, and others publish results as high as 91%. The Dutch Lung Surgery Audit is a clinical database that registers the clinical and pathologic TNM of almost all NSCLCpatients who undergo operations in the Netherlands. The objective of this study was to determine the accuracy of clinical staging of NSCLC. METHODS: Prospective data were derived from the Dutch Lung Surgery Audit in 2013 and 2014. Patients were included if they had undergone a surgical resection for stage IA to IIIB NSCLC without neoadjuvant treatment and had a positron emission tomography-computed tomography scan as part of the clinical workup. Clinical (c)TNM and pathologic (p)TNM were compared, and whether discrepancy was based on tumor or nodal staging was determined. RESULTS: From 2,834 patients identified, 2,336 (82.4%) fulfilled the inclusion criteria and had complete data. Of these 2,336, 1,276 (54.6%) were staged accurately, 707 (30.3%) were clinically understaged, and 353 (15.1%) were clinically overstaged. In the understaged group, 346 patients had a higher pN stage (14.8%), of which 148 patients had unforeseen N2 disease (6.3%). In the overstaged group, 133 patients had a cN that was higher than the pN (5.7%). CONCLUSIONS: Accuracy of NSCLC staging in the Netherlands is low (54.6%), even in the era of positron emission tomography-computed tomography. Especially accurate nodal staging remains challenging. Future efforts should include the identification of specific pitfalls in NSCLC staging.
Authors: Naomi Beck; Fieke Hoeijmakers; Erwin M Wiegman; Hans J M Smit; Franz M Schramel; Willem H Steup; Ad F T M Verhagen; Wilhelmina H Schreurs; Michel W J M Wouters Journal: J Thorac Dis Date: 2018-10 Impact factor: 2.895
Authors: Raymond U Osarogiagbon; Matthew P Smeltzer; Nicholas R Faris; Meredith A Ray; Carrie Fehnel; Phillip Ojeabulu; Olawale Akinbobola; Meghan Meadows-Taylor; Laura M McHugh; Ahmed M Halal; Paul Levy; Vishal Sachdev; David Talton; Lynn Wiggins; Xiao-Ou Shu; Yu Shyr; Edward T Robbins; Lisa M Klesges Journal: J Thorac Oncol Date: 2021-02-16 Impact factor: 15.609
Authors: Meredith A Ray; Carrie Fehnel; Olawale Akinbobola; Nicholas R Faris; Meghan Taylor; Alicia Pacheco; Matthew P Smeltzer; Raymond U Osarogiagbon Journal: J Thorac Oncol Date: 2021-02-12 Impact factor: 15.609
Authors: Jon R Pluyter; Igor Jacobs; Sander Langereis; David Cobben; Sharon Williams; Jeannine Curfs; Ben van den Borne Journal: Transl Lung Cancer Res Date: 2020-08